WERI-Rb-1 Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Head-Neck cancer cell lines

Organism

Human

Donor History

Retinoblastoma

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS and 0.01 mg/mL insulin. Freeze medium: As a cryopreservation medium

,

we use 50% basal medium + 40% FBS + 10% DMSO

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/WERI-Rb-1-Cells/300632

SKU: 300632 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The WERI-Rb-1 cell line is derived from a retinoblastoma, a rare malignant tumor of the retina that typically manifests in early childhood. This cell line was established to provide a consistent and replicable model for the study of retinoblastoma biology, offering insights into the genetic, molecular, and cellular mechanisms underlying this form of cancer. WERI-Rb-1 cells are particularly valued in oncological research for their utility in investigating the pathophysiological processes and potential therapeutic targets for retinoblastoma.

WERI-Rb-1 cells exhibit characteristics typical of retinoblastoma, including the expression of neuronal markers and the capability to form cell aggregates resembling Flexner-Wintersteiner rosettes, a hallmark of retinoblastoma histology. These cells have been used extensively to study the role of oncogenes and tumor suppressor genes in cancer development, with a focus on the RB1 gene, mutations of which are pivotal in the etiology of retinoblastoma. Furthermore, WERI-Rb-1 serves as an important tool in the evaluation of chemotherapeutic agents and novel drug delivery systems aimed at improving treatment outcomes for retinoblastoma patients.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.